AU2437900A - Piperidinylquinolines as protein tyrosine kinase inhibitors - Google Patents
Piperidinylquinolines as protein tyrosine kinase inhibitorsInfo
- Publication number
- AU2437900A AU2437900A AU24379/00A AU2437900A AU2437900A AU 2437900 A AU2437900 A AU 2437900A AU 24379/00 A AU24379/00 A AU 24379/00A AU 2437900 A AU2437900 A AU 2437900A AU 2437900 A AU2437900 A AU 2437900A
- Authority
- AU
- Australia
- Prior art keywords
- piperidinylquinolines
- tyrosine kinase
- kinase inhibitors
- protein tyrosine
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9901236.1A GB9901236D0 (en) | 1999-01-20 | 1999-01-20 | Medicaments |
GB9901236 | 1999-01-20 | ||
GB9923936 | 1999-10-08 | ||
GBGB9923936.0A GB9923936D0 (en) | 1999-10-08 | 1999-10-08 | Compounds |
PCT/EP2000/000350 WO2000043383A1 (en) | 1999-01-20 | 2000-01-17 | Piperidinylquinolines as protein tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2437900A true AU2437900A (en) | 2000-08-07 |
Family
ID=26315007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU24379/00A Abandoned AU2437900A (en) | 1999-01-20 | 2000-01-17 | Piperidinylquinolines as protein tyrosine kinase inhibitors |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1144404A1 (hr) |
JP (1) | JP2002535323A (hr) |
AU (1) | AU2437900A (hr) |
WO (1) | WO2000043383A1 (hr) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9914486D0 (en) | 1999-06-21 | 1999-08-18 | Smithkline Beecham Plc | Medicaments |
US6403610B1 (en) | 1999-09-17 | 2002-06-11 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them |
FR2798656B1 (fr) * | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
US6803369B1 (en) | 2000-07-25 | 2004-10-12 | Smithkline Beecham Corporation | Compounds and methods for the treatment of neoplastic disease |
MXPA03000708A (es) | 2000-07-26 | 2003-06-04 | Smithkline Beecham Plc | Aminopiperidin quinolinas y sus analogos azaisostericos con actividad antibacteriana. |
US6603005B2 (en) | 2000-11-15 | 2003-08-05 | Aventis Pharma S.A. | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them |
FR2816618B1 (fr) | 2000-11-15 | 2002-12-27 | Aventis Pharma Sa | Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent |
GB0031086D0 (en) * | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
GB0101577D0 (en) * | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
FR2822154B1 (fr) * | 2001-03-13 | 2005-10-21 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
US6602884B2 (en) | 2001-03-13 | 2003-08-05 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
GB0118238D0 (en) * | 2001-07-26 | 2001-09-19 | Smithkline Beecham Plc | Medicaments |
EP1470125A1 (en) | 2002-01-29 | 2004-10-27 | Glaxo Group Limited | Aminopiperidine derivatives |
JP4508650B2 (ja) * | 2002-01-29 | 2010-07-21 | グラクソ グループ リミテッド | アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物 |
AR040336A1 (es) | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto |
AR040335A1 (es) | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto |
FR2842807A1 (fr) | 2002-07-23 | 2004-01-30 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, procede et intermediaires de preparation et compositions les renfermant |
GB0217294D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicaments |
FR2844268B1 (fr) * | 2002-09-11 | 2004-10-22 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent |
FR2844270B1 (fr) * | 2002-09-11 | 2006-05-19 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent |
US6835841B2 (en) | 2002-09-13 | 2004-12-28 | Bristol-Myers Squibb Company | Asymmetric catalytic hydrogenation process for preparation of chiral cyclic β-aminoesters |
EP1560821B8 (en) | 2002-11-05 | 2010-05-19 | Glaxo Group Limited | Antibacterial agents |
DE60324179D1 (de) | 2002-12-04 | 2008-11-27 | Glaxo Group Ltd | Chinoline und stickstoffhaltige derivatedavon und deren verwendung als antibakterielle mittel |
PT1622569E (pt) | 2003-04-24 | 2016-03-03 | Incyte Corp | Derivados de aza espiro alcanos como inibidores de metaloproteases |
SG166019A1 (en) | 2004-01-23 | 2010-11-29 | Janssen Pharmaceutica Nv | Quinoline derivatives and use thereof as mycobacterial inhibitors |
FR2867472B1 (fr) * | 2004-03-12 | 2008-07-18 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
FR2872164B1 (fr) * | 2004-06-29 | 2006-11-17 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
DE602005021133D1 (de) * | 2004-10-05 | 2010-06-17 | Actelion Pharmaceuticals Ltd | Neue piperidin-antibiotika |
EP1846411A4 (en) | 2005-01-25 | 2010-08-04 | Glaxo Group Ltd | ANTIBACTERIAL ACTIVE SUBSTANCES |
EP1846418A4 (en) | 2005-01-25 | 2009-12-23 | Glaxo Group Ltd | ANTIBACTERIAL ACTIVE SUBSTANCES |
EP1845995A4 (en) | 2005-01-25 | 2010-03-03 | Glaxo Group Ltd | ANTIBACTERIAL AGENTS |
US7605169B2 (en) | 2005-01-25 | 2009-10-20 | Glaxo Group Limited | Antibacterial agents |
JP2008528586A (ja) | 2005-01-25 | 2008-07-31 | グラクソ グループ リミテッド | 抗菌剤 |
EP1853586B1 (en) * | 2005-02-18 | 2013-07-24 | AstraZeneca AB | Antibacterial piperidine derivatives |
MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
EP1981881B1 (en) | 2006-01-26 | 2011-12-07 | Actelion Pharmaceuticals Ltd. | Tetrahydropyrane antibiotics |
WO2007118130A2 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Antibacterial agents |
KR20090130347A (ko) * | 2007-05-09 | 2009-12-22 | 화이자 인코포레이티드 | 치환된 헤테로사이클릭 유도체 및 조성물 및 항균제로서의 이의 약학적 용도 |
EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
WO2016138988A1 (en) * | 2015-03-02 | 2016-09-09 | University Of Copenhagen | Piperazine inhibitors of bacterial gyrase and topoisomerase iv |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
US6207679B1 (en) * | 1997-06-19 | 2001-03-27 | Sepracor, Inc. | Antimicrobial agents uses and compositions related thereto |
KR20010014030A (ko) * | 1997-06-19 | 2001-02-26 | 더글라스이.리디치 | 퀴놀린-인돌 항균제, 이들의 용도 및 조성물 |
JP2002501061A (ja) * | 1998-01-26 | 2002-01-15 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 抗菌剤用キノリン誘導体 |
-
2000
- 2000-01-17 WO PCT/EP2000/000350 patent/WO2000043383A1/en not_active Application Discontinuation
- 2000-01-17 JP JP2000594799A patent/JP2002535323A/ja active Pending
- 2000-01-17 EP EP00902605A patent/EP1144404A1/en not_active Withdrawn
- 2000-01-17 AU AU24379/00A patent/AU2437900A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2002535323A (ja) | 2002-10-22 |
EP1144404A1 (en) | 2001-10-17 |
WO2000043383A1 (en) | 2000-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2437900A (en) | Piperidinylquinolines as protein tyrosine kinase inhibitors | |
HUS1700048I1 (hu) | Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai | |
HK1244797A1 (zh) | 環蛋白酪氨酸激酶抑制劑 | |
AU2002334355A1 (en) | Protein tyrosine kinase inhibitors | |
EG24381A (en) | Tyrosine kinase inhibitors | |
PL346934A1 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
HK1049154A1 (zh) | 作為酪氨酸激酶抑制劑的2-吡唑啉-5-酮 | |
AU2563900A (en) | Quinoline derivatives as tyrosine kinase inhibitors | |
AU6411698A (en) | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | |
AU6998000A (en) | Substituted indolinones as tyrosine kinase inhibitors | |
AU2000240570A1 (en) | Pyrrolopyrimidines as tyrosine kinase inhibitors | |
EP1161433A4 (en) | TYROSINE KINASE INHIBITORS | |
AU1371999A (en) | Benzothiazole protein tyrosine kinase inhibitors | |
AU2728201A (en) | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | |
AU2002361577A1 (en) | Tyrosine kinase inhibitors | |
AU2002357193A1 (en) | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | |
AU2002348394A1 (en) | Tyrosine kinase inhibitors | |
AU2001247882A1 (en) | Tricyclic protein kinase inhibitors | |
AU5215700A (en) | Substituted indolinone as tyrosine kinase inhibitors | |
AU2002348020A1 (en) | Tyrosine kinase inhibitors | |
AU2576501A (en) | Protein kinase inhibitors | |
AU2002348393A1 (en) | Tyrosine kinase inhibitors | |
AU2002323406A1 (en) | Tyrosine kinase inhibitors | |
AU2002327534A1 (en) | Tyrosine kinase inhibitors | |
AU2002253350A1 (en) | 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |